Moderna COVID vaccine sales forecast unchanged even as COVAX program cuts orders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Moderna (MRNA) Shares Rally After Topping Q2 Estimates
August 3, 2022 9:58 AM EDTModerna (NASDAQ: MRNA) shares jumped more than 13% in early Wednesday trading after it posted earnings before the open Wednesday, topping analyst earnings and revenue consensus estimates.
The pharmaceutical company revealed second-quarter earnings of $5.24 per share, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.
Moderna's said... More
